Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 24, Issue 2, Pages 139-150
Publisher
Elsevier BV
Online
2023-01-13
DOI
10.1016/s1470-2045(22)00738-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent
- (2022) Benjamin A. Derman et al. JAMA Oncology
- Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
- (2021) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
- (2021) Philippe Moreau et al. LANCET ONCOLOGY
- Ixazomib Plus Lenalidomide/Dexamethasone (IRd) Versus Lenalidomide /Dexamethasone (Rd) Maintenance after Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Results of the Spanish GEM2014MAIN Trial
- (2021) Laura Rosinol et al. BLOOD
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
- (2021) Luciano J. Costa et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
- (2021) Francesca Gay et al. LANCET ONCOLOGY
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
- (2020) Jagoda Jasielec et al. BLOOD
- International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
- (2020) Luciano J. Costa et al. LEUKEMIA
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma
- (2019) Edward A. Stadtmauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
- (2018) Meletios A Dimopoulos et al. LANCET
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial
- (2017) L Rosiñol et al. LEUKEMIA
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
- (2012) T Kalina et al. LEUKEMIA
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now